Previous close | 5.65 |
Open | 5.70 |
Bid | 5.86 x 100 |
Ask | 5.98 x 100 |
Day's range | 5.60 - 6.01 |
52-week range | 2.86 - 7.76 |
Volume | |
Avg. volume | 152,188 |
Market cap | 251.118M |
Beta (5Y monthly) | 1.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.48 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.00 |
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today
We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears the...
Verrica Pharmaceuticals ( NASDAQ:VRCA ) Full Year 2023 Results Key Financial Results Net loss: US$67.0m (loss widened...